BR112012017350A2 - "polipeptídeo de fusão contra tumor induzido por vírus eb e mutante de colicina ia". - Google Patents
"polipeptídeo de fusão contra tumor induzido por vírus eb e mutante de colicina ia".Info
- Publication number
- BR112012017350A2 BR112012017350A2 BR112012017350-2A BR112012017350A BR112012017350A2 BR 112012017350 A2 BR112012017350 A2 BR 112012017350A2 BR 112012017350 A BR112012017350 A BR 112012017350A BR 112012017350 A2 BR112012017350 A2 BR 112012017350A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutant
- virus
- colicin
- fusion polypeptide
- induced tumor
- Prior art date
Links
- 108010073254 Colicins Proteins 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"polipeptídeo de fusão contra tumor induzido por vírus eb e mutante de colicina ia" a presente invenção fornece um polipeptídeo de fusão contra tumor induzido pelo vírus eb, que compreende um anticorpo ou um mimético anticorpo contra vírus eb e uma colicina formadora de canal de íon selecionada de e1, ia, ib, a, b, n e seus mutantes. a presente invenção também fornece uma colicina ia mutante, que compreende mutações de g11a, h22g, a26g, v31l e h4od. a presente invenção também fornece um gene, vetor, método de preparação e uso do polipeptídeo de fusão, e fornece um gene e uso do mutante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910242838.0 | 2009-12-17 | ||
CN2009102428380A CN102101888B (zh) | 2009-12-17 | 2009-12-17 | 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法 |
PCT/CN2010/070762 WO2011072501A1 (zh) | 2009-12-17 | 2010-02-26 | 抗EB病毒诱发的肿瘤的融合多肽和大肠菌素Ia突变体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012017350A2 true BR112012017350A2 (pt) | 2018-07-24 |
Family
ID=44154977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012017350-2A BR112012017350A2 (pt) | 2009-12-17 | 2010-02-26 | "polipeptídeo de fusão contra tumor induzido por vírus eb e mutante de colicina ia". |
Country Status (30)
Country | Link |
---|---|
US (1) | US8883161B2 (pt) |
EP (1) | EP2514768B1 (pt) |
JP (1) | JP5683603B2 (pt) |
KR (1) | KR101464842B1 (pt) |
CN (1) | CN102101888B (pt) |
AP (1) | AP3535A (pt) |
AU (1) | AU2010333588B2 (pt) |
BR (1) | BR112012017350A2 (pt) |
CA (1) | CA2784784C (pt) |
CL (1) | CL2012001609A1 (pt) |
CO (1) | CO6541633A2 (pt) |
CR (1) | CR20120329A (pt) |
CU (1) | CU20120096A7 (pt) |
DK (1) | DK2514768T3 (pt) |
DO (1) | DOP2012000164A (pt) |
EA (1) | EA030638B1 (pt) |
ES (1) | ES2634944T3 (pt) |
GE (1) | GEP20156228B (pt) |
HK (1) | HK1159123A1 (pt) |
HU (1) | HUE033298T2 (pt) |
IL (1) | IL220296A (pt) |
MA (1) | MA33921B1 (pt) |
MX (1) | MX2012006952A (pt) |
NZ (1) | NZ600729A (pt) |
PE (1) | PE20121722A1 (pt) |
SG (1) | SG181553A1 (pt) |
TN (1) | TN2012000253A1 (pt) |
UA (1) | UA104933C2 (pt) |
WO (1) | WO2011072501A1 (pt) |
ZA (1) | ZA201205217B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
US10071358B2 (en) * | 2011-12-08 | 2018-09-11 | Protein Design Lab, Ltd. | Antibiotic preparation method and platform system based on same |
WO2016023491A1 (en) * | 2014-08-12 | 2016-02-18 | The University Of Hong Kong | Biophosphonate compounds and gamma delta t cell-mediated therapy for treating epstein-barr virus-associated disorders |
CN104604799B (zh) * | 2015-02-05 | 2017-11-21 | 南华大学 | 一种鉴定eb病毒对淋巴瘤的诱发性的方法 |
US20210373004A1 (en) * | 2018-11-19 | 2021-12-02 | Bioaster | Methods and reagents for multiplex binding experiments |
CN111333724B (zh) * | 2018-12-19 | 2022-03-15 | 中国人民解放军军事科学院军事医学研究院 | 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用 |
CN111848817B (zh) * | 2020-07-28 | 2021-11-09 | 中国农业大学 | 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用 |
CN112125959B (zh) * | 2020-10-10 | 2022-07-29 | 中山大学肿瘤防治中心 | 一种抑制eb病毒的肽和编码该肽的dna及其应用 |
CN113880914B (zh) * | 2021-04-25 | 2023-11-21 | 内蒙古农业大学 | 一种抗肿瘤多肽及其衍生物 |
CN114369158B (zh) * | 2021-09-28 | 2024-04-19 | 北京亦科信息菌素研究院有限公司 | 一种抗新冠病毒的信息菌素及其应用 |
CN113999304B (zh) * | 2021-10-13 | 2023-10-24 | 北京市农林科学院 | 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1164612C (zh) | 2001-09-11 | 2004-09-01 | 四川新泰克控股有限责任公司 | 人工组合的抗菌工程多肽及其制备方法 |
CN1314806C (zh) | 2005-01-14 | 2007-05-09 | 四川大学 | 小型化抗eb病毒肿瘤多肽及其应用与制备方法 |
CN1274829C (zh) | 2004-12-10 | 2006-09-13 | 四川大学华西医院 | 抗eb病毒所致肿瘤多肽及其应用与制备方法 |
WO2007083175A1 (en) * | 2006-01-17 | 2007-07-26 | West China Hospital, Sichuan University | Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
CN101643501B (zh) * | 2008-11-07 | 2012-06-20 | 畿晋庆三联(北京)生物技术有限公司 | 一种新型抗生素及其核苷酸序列、制备方法与应用 |
CN101633699B (zh) * | 2009-09-02 | 2012-02-15 | 畿晋庆堂国际生物技术有限公司 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
-
2009
- 2009-12-17 CN CN2009102428380A patent/CN102101888B/zh not_active Expired - Fee Related
-
2010
- 2010-02-26 UA UAA201208633A patent/UA104933C2/uk unknown
- 2010-02-26 MA MA35062A patent/MA33921B1/fr unknown
- 2010-02-26 GE GEAP201012791A patent/GEP20156228B/en unknown
- 2010-02-26 BR BR112012017350-2A patent/BR112012017350A2/pt not_active Application Discontinuation
- 2010-02-26 CA CA2784784A patent/CA2784784C/en not_active Expired - Fee Related
- 2010-02-26 US US13/516,605 patent/US8883161B2/en not_active Expired - Fee Related
- 2010-02-26 NZ NZ600729A patent/NZ600729A/en not_active IP Right Cessation
- 2010-02-26 MX MX2012006952A patent/MX2012006952A/es active IP Right Grant
- 2010-02-26 AP AP2012006327A patent/AP3535A/xx active
- 2010-02-26 EA EA201270655A patent/EA030638B1/ru not_active IP Right Cessation
- 2010-02-26 DK DK10836940.6T patent/DK2514768T3/en active
- 2010-02-26 HU HUE10836940A patent/HUE033298T2/en unknown
- 2010-02-26 KR KR1020127018638A patent/KR101464842B1/ko active IP Right Grant
- 2010-02-26 ES ES10836940.6T patent/ES2634944T3/es active Active
- 2010-02-26 JP JP2012543448A patent/JP5683603B2/ja not_active Expired - Fee Related
- 2010-02-26 SG SG2012041786A patent/SG181553A1/en unknown
- 2010-02-26 WO PCT/CN2010/070762 patent/WO2011072501A1/zh active Application Filing
- 2010-02-26 PE PE2012000834A patent/PE20121722A1/es active IP Right Grant
- 2010-02-26 EP EP10836940.6A patent/EP2514768B1/en active Active
- 2010-02-26 AU AU2010333588A patent/AU2010333588B2/en not_active Ceased
-
2011
- 2011-12-14 HK HK11113462.9A patent/HK1159123A1/xx not_active IP Right Cessation
-
2012
- 2012-05-24 TN TNP2012000253A patent/TN2012000253A1/en unknown
- 2012-06-11 IL IL220296A patent/IL220296A/en not_active IP Right Cessation
- 2012-06-12 CU CU2012000096A patent/CU20120096A7/es active IP Right Grant
- 2012-06-12 CO CO12098450A patent/CO6541633A2/es unknown
- 2012-06-13 DO DO2012000164A patent/DOP2012000164A/es unknown
- 2012-06-14 CL CL2012001609A patent/CL2012001609A1/es unknown
- 2012-06-15 CR CR20120329A patent/CR20120329A/es unknown
- 2012-07-13 ZA ZA2012/05217A patent/ZA201205217B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012017350A2 (pt) | "polipeptídeo de fusão contra tumor induzido por vírus eb e mutante de colicina ia". | |
Moyer et al. | Binding of STIL to Plk4 activates kinase activity to promote centriole assembly | |
MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
AU2017204797B2 (en) | Antibodies with modified isoelectric points | |
Sancier et al. | Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells | |
Fisher et al. | Uptake of biotin by Chlamydia Spp. through the use of a bacterial transporter (BioY) and a host-cell transporter (SMVT) | |
PH12014502880A1 (en) | Lyophilized therapeutic peptibody formulations | |
HN2012001223A (es) | Antagonistas de pcsk 9 | |
NZ602119A (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
MX2009008175A (es) | Metodos para producir vacunas basadas en levadura. | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
NZ605873A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
NZ704098A (en) | Epsps mutants | |
SG196784A1 (en) | Stem cell cultures | |
Yang et al. | Cervical cancer growth is regulated by a c-ABL–PLK1 signaling axis | |
MX2014010664A (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
WO2007051063A3 (en) | Gpcr expressing cell lines and antibodies | |
WO2014100073A3 (en) | Expression vectors for recombinant protein production in mammalian cells | |
MX342907B (es) | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. | |
Piek et al. | The role of oxidoreductases in determining the function of the neisserial lipid A phosphoethanolamine transferase required for resistance to polymyxin | |
MX2009012420A (es) | Reovirus mutantes y metodos para elaboracion y uso. | |
MX2013007146A (es) | Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. | |
WO2019126097A8 (en) | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof | |
CA3043675C (en) | Joint implant for new tissue formation at the joint | |
MX2018016417A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |